Alder Therapeutics

Focus: Alder Therapeutics is a Swedish stem cell and cell therapy biotech founded in 2022, operating at mid-cap scale with 1,001-5,000 employees as a publicly listed entity. The company develops therapies across migraine, oncology, immunology, and rare genetic disorders.

Cell Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

1001-5000

Total Funding

$20M

Open Jobs

About Alder Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Alder Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

circumcision

Balanitis Xerotica Obliterans (BXO)

N/A

Clinical Trials (1)

NCT02854995Circumcision Versus Preputioplasty for BXO in Children

N/A

Help build intelligence for Alder Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides liquidity and stability relative to venture-backed peers, with access to capital markets for growth
Diversified pipeline across 5 active programs spanning multiple therapeutic areas reduces single-asset risk
Phase 3 program (eptinezumab in migraine) with 7 active trials offers near-term value creation catalysts

Watch Out For

Zero active job openings despite 1,001-5,000 headcount suggests limited hiring or internal restructuring in progress
Company founded only in 2022 yet public status raises questions about acquisition/merger origins and organizational maturity
Pipeline heavily reliant on out-licensed or acquired assets (adalimumab, burosumab, eptinezumab) rather than proprietary innovation

Generated by Claude from Alder Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Qualitative study

Palliative Medicine

N/A

Clinical Trials (1)

NCT04519632Paediatric Palliative Care Pain Management in the Community

N/A

Pull through

Hirschsprung Disease

N/A

Clinical Trials (1)

NCT05450991Long-term Qualitative and Quantitative Outcomes of Children With Hirschsprung's Disease and Anorectal Malformations

N/A

Therapist

Ataxia

N/A

Clinical Trials (1)

NCT03945682The ASsessment and Physiotherapy managEment of Ataxia in Children Following Surgical Resection of Posterior Fossa Tumour

N/A

Observational study of tissue specimens

Hirschsprung Disease

N/A

Clinical Trials (1)

NCT06590142Hirschsprung's Advances; Working Towards Autologous tIssue therapIes

N/A

TCD

Cerebral Blood Flow and Neonates During Acute Respiratory Failure

N/A

Clinical Trials (1)

NCT03733795Cerebral Perfusion and Acute Respiratory Failure

N/A

Long-Term Outcomes of Hip Interventions for Children With Cerebral Palsy

Cerebral Palsy

N/A

Innova Lateral Flow Test

SARS-CoV-2 Infection

N/A

Clinical Trials (1)

NCT05614427The LAVA (Lateral Flow Antigen Validation and Applicability) 2 Study for COVID-19

N/A

Interview

Young People With All Long-term Health Conditions

N/A

Clinical Trials (1)

NCT05867745The National Transition Evaluation Study

N/A

Abdominal Surgery for congenital gut malformation in the first 5 days of life.

Gastroschisis

N/A

Clinical Trials (1)

NCT06731855An Exploratory Physiological Study of Post-operative Recovery in Surgical Neonates and Dimethylarginine:Arginine Levels

N/A

Innova Lateral Flow Device

This is a Pilot Study Which Aims to Assess the Validity and Applicability of Lateral Flow Assays (LFAs) Which Can be Used as a Point of Care Test for COVID-19

N/A

Clinical Trials (1)

NCT04629157The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19

N/A

Microdebrider

Recurrent Respiratory Papillomatosis

N/A

Clinical Trials (1)

NCT03465280Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)

N/A

Questionnaire

Immune Suppression

N/A

Clinical Trials (1)

NCT04382508Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.

N/A

Babies With Enterocolitis - A Study of Faecal Calprotectin in Hirschsprung Disease (The BEACH Study)

Hirschprung's Disease

N/A

Clinical Trials (1)

NCT06592534Babies With Enterocolitis - A Study of Faecal Calprotectin in Hirschsprung Disease (The BEACH Study)

N/A

aortic arch surgery

Cardiac

N/A

Clinical Trials (1)

NCT03047876Brain Vascular Reactivity to Hypothermic Circulatory Arrest With Antegrade Cerebral Perfusion During Aortic Arch Surgery

N/A

Observation - Nailfold capillaroscopy

Systemic Sclerosis

N/A

Clinical Trials (1)

NCT06291142Early Diagnosis of SSc in the General Rheumatology Clinic - Pilot

N/A

Exploring and Measuring the Impact of Steroids in Children and Young People

Rheumatic Diseases

N/A

Clinical Trials (1)

NCT07350395Exploring and Measuring the Impact of Steroids in Children and Young People

N/A

Live Music

Pain

N/A

Clinical Trials (1)

NCT03956667iMpact of therapeUtic Live muSic on Pain and Distress Levels During Interventions in the paediatriC Emergency Department

N/A

Developing Allogeneic Musculoskeletal Therapies

Osteoarthritis

N/A

Clinical Trials (1)

NCT06167928Developing Allogeneic Musculoskeletal Therapies

N/A

Cefuroxime

Cardiac Event

N/A

Clinical Trials (1)

NCT02850250Pharmacokinetics of Post Operative Cefuroxime in Infants Undergoing Cardiac Surgery

N/A

Play therapy

Pain

N/A

Clinical Trials (1)

NCT02832050PLAY Therapy Intervention: Re-Modelling Patient Experience (The PLAYTIME Study)

N/A

PlayPhysio

Cystic Fibrosis in Children

N/A

Clinical Trials (1)

NCT05469711PlayPhysio: Making Physio Fun

N/A

LOOP + mHealth technology assisted exercise counselling

Obesity, Adolescent

N/A

Clinical Trials (1)

NCT04854915mHealth Biometrics for Young People With Obesity (MOTIVATE- LOOP)

N/A

A Pilot Study of Migraine and Appetite Behaviour in Children

Migraine Disorders

N/A

Clinical Trials (1)

NCT00930852A Pilot Study of Migraine and Appetite Behaviour in Children

N/A

Intervention group

Inflammatory Bowel Diseases

N/A

Clinical Trials (1)

NCT03170622Evaluation of Faecal Volatile Organic Compounds in the Diagnosis of Paediatric Inflammatory Bowel Disease

N/A

Quality of Life

Cystic Fibrosis

N/A

Clinical Trials (1)

NCT05986045ENHANCE- Establishing Natural History in an Advanced New CF Care Era

N/A

Calprotectin and Gut Disease Study

Congenital Heart Disease

N/A

Clinical Trials (1)

NCT07112794Calprotectin and Gut Disease Study

N/A

Online self-compassion intervention

Diabetes Mellitus, Type 1

N/A

Clinical Trials (1)

NCT03504605Impact of Parental Perfectionistic Cognitions Self-compassion Intervention Effects on Shame in Child Health Context

N/A

burosumab

X-linked Hypophosphatemia (XLH)

N/A

Clinical Trials (1)

NCT07183579Effective Dosing of Burosumab in XLH

N/A

Closed-loop system

Diabetes Mellitus

N/A

Clinical Trials (1)

NCT02871089Closed Loop From Onset in Type 1 Diabetes

N/A

CamAPS FX using faster insulin aspart

Type 1 Diabetes Mellitus

N/A

Clinical Trials (1)

NCT04759144FASter Insulin in Closed-loop Technology in Children

N/A

Advanced MRI

Intraventricular Hemorrhage Neonatal

N/A

Clinical Trials (1)

NCT07412886Advanced MRI in IVH

N/A

ALD1910

Migraine

Phase 1

ALD403

Migraine

Phase 1

Clinical Trials (1)

NCT01772524Safety, Efficacy and Pharmacokinetics of ALD403

Phase 1

ALD403

Migraine Disorders

Phase 1

Clinical Trials (1)

NCT01579383Safety Tolerability and Pharmacokinetics of ALD403

Phase 1

ch14.18/CHO

Neuroblastoma

Phase 1/2

ALD403

Migraine Disorders

Phase 2

Clinical Trials (1)

NCT02275117A Multicenter Assessment of ALD403 in Chronic Migraine

Phase 2

Intravenous Methylprednisolone

Myelitis, Transverse

Phase 3

Clinical Trials (1)

NCT02398994A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis

Phase 3

ALD403

Migraine Disorders

Phase 3

Clinical Trials (1)

NCT02559895A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

Phase 3

eptinezumab

Migraine Disorders

Phase 3

Clinical Trials (2)

NCT02985398An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

Phase 3

NCT02974153Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

Phase 3

Remifentanil and/or propofol

Children

Phase 3

Clinical Trials (1)

NCT02481791Study to Evaluate the Optimal Dose of Remifentanil During MRI of the Heart Under General Anaesthesia

Phase 3

Ketogenic diet

Epilepsy

Phase 4

Clinical Trials (1)

NCT02205931Ketogenic Diet in Infants With Epilepsy (KIWE)

Phase 4

adalimumab

Uveitis

Phase 4

Clinical Trials (1)

NCT04725422CHronic Nonbacterial Osteomyelitis International Registry

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2022

Portfolio: 41 clinical trials

Top TAs: Neurology, Metabolic Diseases, Respiratory

Publications: 25 in PubMed

Therapeutic Area Focus

11 pipeline

5 pipeline

3 pipeline

2 pipeline

2 pipeline

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Preparation of Targeted Lipid Nanoparticles by Insertion of Either Tetrazine-trans-Cyclooctene or Thiol-Maleimide Micelles.

Bioconjugate chemistry

2026

PMID:41615769

Subretinal Injection Volume Correlates to Persistent Outer Retinal Thinning in the Pig Eye.

Cardiovascular

1 pipeline

Investigative ophthalmology & visual science

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo